{
  "doc_id": "Mixed-Connective-Tissue-Disease-(MCTD)",
  "doc_filename": "Mixed-Connective-Tissue-Disease-(MCTD).pdf",
  "top_entities": [
    {
      "name": "mixed connective tissue disease",
      "mention_count": 1,
      "entity_type": "disease"
    },
    {
      "name": "Anti-RNP",
      "mention_count": 1,
      "entity_type": "drug"
    }
  ],
  "file_size_bytes": 1650,
  "file_size_human": "1.6 KB",
  "file_extension": ".pdf",
  "pdf_title": "(anonymous)",
  "pdf_author": "(anonymous)",
  "pdf_page_count": 1,
  "pdf_creation_date": "2026-01-07T22:25:17",
  "doi": null,
  "doi_url": null,
  "document_type_code": "CRM",
  "document_type_name": "Clinical Research Materials",
  "document_type_group": "Clinical Research Materials",
  "classification_confidence": 0.25,
  "title": "Mixed Connective Tissue Disease (MCTD) Diagnostic Guidelines",
  "short_description": "Clinical guidance document outlining diagnostic criteria and testing methods for Mixed Connective Tissue Disease (MCTD).",
  "long_description": "This clinical document provides comprehensive information on the diagnostic approach for Mixed Connective Tissue Disease (MCTD), a rare autoimmune condition. The document details the multi-faceted diagnostic process which includes thorough clinical evaluation, comprehensive patient history assessment, identification of characteristic clinical findings, and specialized laboratory testing. Particular emphasis is placed on the importance of blood tests that detect abnormally elevated levels of antibodies to the U1 small nuclear ribonucleoprotein (anti-RNP), which serves as a key diagnostic marker for MCTD. This resource appears to be designed for healthcare professionals involved in the diagnosis and management of connective tissue disorders.",
  "document_date": "2026-01-07T22:25:17",
  "document_date_source": "pdf_metadata",
  "extraction_timestamp": "2026-02-05T01:38:59.751477"
}